

ANZTCT Registry

Annual Data Summary 2025

Contents

Introduction	1
Registry data 1992-2025	2
Transplant activity	2
Autologous and allogeneic transplants + standard of care CAR-T	2
Stem cell source for autologous transplants	3
Stem cell source for allogeneic transplants.....	3
Indications for autologous transplant	4
Indications for allogeneic transplant.....	4
Donor source for allogeneic transplants.....	5
Transplant activity by age group	5
Registry activity 2025.....	6
Haematopoietic cell transplant and CAR-T activity summary	6
Transplant activity by state.....	7
Transplant activity by country.....	8
Transplant activity 2024 by state / country and hospital type.....	9
Transplant and recipient characteristics	10
Transplant recipients by age group.....	10
Stem cell source by donor type 2025.....	11
Conditioning intensity for allogeneic transplants by age group 2025	11
HLA compatibility for allogeneic transplants	12
Indication for transplant	13
Recipients aged 0-15 - indication by transplant type	13
Recipients aged 16+ - indication by transplant type	14
Unrelated donor transplants	15
Stem cell source - recipients aged 0-15.....	15
Stem cell source - recipients aged 16+	15
Stem cell source for unrelated transplants - Australia and New Zealand	16
Donor country for Australian unrelated donor transplants.....	17
Australian peripheral blood and marrow transplants.....	17
Australian cord blood transplants.....	17
Donor country - marrow and peripheral blood.....	18
Donor country - cord blood.....	18
Adverse events in the first 100 days	19
Performance status 1 year post transplant (Lansky/Karnofsky).....	19
CAR-T activity and outcomes	20
CAR-T activity by state and patient residence 2025 (Australian public funded)	20
Overall survival – First CAR-T infusion large B-cell lymphoma 2020-24	20
Outcomes in the first year post transplant.....	21
Recipients aged 0-15	21
Acute GVHD 2025 all grades – matched sibling donor.....	21
Acute GVHD 2025 all grades – other related donor	21

Acute GVHD 2025 all grades – unrelated donor	22
Acute GVHD 2025 grade II and above – matched sibling donor	22
Acute GVHD 2025 grade II and above – other related donor	23
Acute GVHD 2025 grade II and above – unrelated donor	23
Chronic GVHD 2010-24 – matched sibling donor	24
Chronic GVHD 2010-24 – other related donor	24
Chronic GVHD 2010-24 – unrelated donor	25
One year survival 2016-2024	25
Recipients aged 16+	26
Acute GVHD 2025 all grades - matched sibling donor	26
Acute GVHD 2025 all grades – other related donor	26
Acute GVHD 2025 all grades – unrelated donor	27
Acute GVHD 2025 grade II and above - matched sibling donor	27
Acute GVHD 2025 grade II and above – other related donor	28
Acute GVHD 2025 grade II and above – unrelated donor	28
Chronic GVHD 2010-24 – matched sibling donor	29
Chronic GVHD 2010-24 – other related donor	29
Chronic GVHD 2010-24 – unrelated donor	30
One year survival 2016-2024	30
Ten-year survival - first transplants 2010-2024	31
Recipients aged 0-15	31
Acute lymphoblastic leukaemia - HLA identical sibling donor	31
Acute lymphoblastic leukaemia - unrelated donor	31
Acute lymphoblastic leukaemia - unrelated cord vs other related donor	32
Acute myeloid leukaemia - HLA identical sibling donor	32
Immune deficiencies	33
Aplastic anaemia	33
Neuroblastoma	34
Medulloblastoma	34
Recipients aged 16+	35
Acute myeloid leukaemia - HLA identical sibling donor	35
Acute myeloid leukaemia - unrelated donor	35
Acute myeloid leukaemia - unrelated cord vs other related donor	36
Acute lymphoblastic leukaemia - HLA identical sibling donor	36
Acute lymphoblastic leukaemia - unrelated donor	37
Acute lymphoblastic leukaemia - unrelated cord vs other related donor	37
Chronic myeloid leukaemia - HLA identical sibling donor	38
Chronic myeloid leukaemia - unrelated donor	38
Myelodysplasia - HLA-identical sibling donor	39
Myelodysplasia - unrelated donor	39
Myeloma by ISS score	40
Hodgkin lymphoma – autologous	40
Non-Hodgkin lymphoma – autologous	41
Non-Hodgkin lymphoma – allogeneic	41
Non-Hodgkin lymphoma – allogeneic by donor type	42

Primary amyloidosis	42
Testicular cancer	43
Aplastic anaemia	43
Ewing sarcoma - adult and paediatric autologous	44
Multiple sclerosis	44
Transplant related mortality	45
100 day and 1 year TRM 2019-2023	45
TRM trends: recipients aged 0-15	45
TRM trends: recipients aged 16+	46
Cause of death post transplant	47
Recipients aged 0-15	47
Primary cause of death post autologous transplant	47
Primary cause of death post allogeneic transplant - first year	48
Contributing causes of TRM in the first year by allogeneic donor type	48
Contributing causes of TRM at 100 days and 1 year post allogeneic transplant	49
Primary cause of death post allogeneic transplant - second year	49
Recipients aged 16+	50
Primary cause of death post autologous transplant	50
Contributing causes of TRM at 100 days and 1 year post autologous transplant	50
Primary cause of death post allogeneic transplant - first year	51
Contributing causes of TRM by allogeneic donor type	51
Contributing causes of TRM at 100 days and 1 year post allogeneic transplant	52
Primary cause of death post allogeneic transplant - second year	52
Contributing centres	53
Australia	53
New Zealand	53
Recent publications	54